RASI’S IN RECOMMENDED HIGHER TARGET DOSES MAY LOWER RISK OF DEATH AND KIDNEY FAILURE IN OCTOGENARIANS WITH HFREF
Ali Ahmed, Paul Heidenreich, Wilbert Aronow, Richard Allman, Charles Faselis, Mo-kyung Sin, Phillip Lam, Gregg Fonarow · 2024
Read RASI’S IN RECOMMENDED HIGHER TARGET DOSES MAY LOWER RISK OF DEATH AND KIDNEY FAILURE IN OCTOGENARIANS WITH HFREF by Ali Ahmed, Paul Heidenreich, Wilbert Aronow, Richard Allman, Charles Faselis, Mo-kyung Sin, Phillip Lam, Gregg Fonarow (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11693328.txt.
Description
Ali Ahmed and co-authors ask whether higher drug doses help the oldest heart failure patients, in this 2024 study. Drugs that block the renin-angiotensin system cut deaths in heart failure with weak pumping. Guidelines urge doctors to push these drugs to set target doses. Yet trials behind those targets left out patients in their eighties, and effects on kidney failure were not checked.
The team studied veterans aged eighty or more with weak heart pumping who took these drugs. They matched patients on target doses with like patients on lower doses. Over five years, the target-dose group had a small but real edge in survival. Signs also pointed to a lower risk of kidney failure, though that link was less firm. The authors back target doses for this age group.
Catalog record
| CREATOR | Ali Ahmed, Paul Heidenreich, Wilbert Aronow, Richard Allman, Charles Faselis, Mo-kyung Sin, Phillip Lam, Gregg Fonarow |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 2 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |